FDMT
$12.19
+$0.54 (4.64%)+4.64%
After HoursLoading chart...
IndexN/A
Market Cap0.64B
Enterprise Value0.40B
Income$-0.05B
Sales$0.00B
EmployeesN/A
P/E-4.74
P/S5.10
P/B0.86
P/C-3.98
EV/EBITDA-2.99
EV/SalesN/A
EPS (ttm)-2.57
EarningsN/A
Gross Margin91.05%
Oper. Margin-187.24%
Profit Margin-164.43%
Volume0.74M
Shs Outstand0.05B
Change4.64%
Dividend Est.N/A
Dividend Ex-DateN/A
Perf YTDN/A
Perf YearN/A
Perf 3YN/A
Perf 5YN/A
Perf 10YN/A
IPON/A
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $37.00K | $20.72M | $3.13M | $18.04M | $13.61M | $6.99M | $14.13M | $5.79M |
| Cost of Revenue | $0.00 | $97.10M | $80.25M | $61.36M | $53.04M | $38.72M | $18.36M | $13.57M |
| Gross Profit | $37.00K | $-76.37M | $-77.12M | $-43.32M | $-39.43M | $-31.73M | $-4.23M | $-7.78M |
| Gross Margin | 100.00% | -368.54% | -2464.81% | -240.17% | -289.64% | -454.22% | -29.95% | -134.42% |
| Operating Expenses | $187.88M | $36.49M | $32.91M | $28.01M | $17.24M | $19.03M | $6.17M | $3.49M |
| Operating Income | $-187.84M | $-112.87M | $-110.03M | $-71.33M | $-56.66M | $-50.76M | $-10.40M | $-11.27M |
| Operating Margin | -507678.38% | -544.65% | -3516.52% | -395.46% | -416.28% | -726.65% | -73.60% | -194.68% |
| Net Income | $-160.87M | $-100.84M | $-107.49M | $-71.32M | $-56.69M | $-49.31M | $-9.55M | $-11.22M |
| Net Margin | -434778.38% | -486.59% | -3435.41% | -395.37% | -416.49% | -705.78% | -67.59% | -193.83% |
| EPS (Basic) | $-2.98 | $-2.58 | $-3.12 | $-2.46 | $-2.12 | $-2.00 | $-0.76 | $-0.76 |
| EBITDA | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Stock Option Compensation Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Earnings Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Sales Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Shares Outstanding | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Market Capitalization | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|
| Cash & Short Term Investments | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Short Term Receivables | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Inventories | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Current Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Current Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Property, Plant & Equipment | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Investments and Advances | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Long-Term Note Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Intangible Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Deferred Tax Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Assets | $560.38M | $339.89M | $261.85M | $353.49M | $288.33M | $58.23M | $96.97M | $27.32M |
| Short Term Debt Incl. Current Port. of LT Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Payable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax Payable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Current Liabilities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Current Liabilities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Long Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Provision for Risks Charges | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Deferred Tax Liabilities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Liabilities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $49.78M | $32.06M | $30.51M | $34.38M | $31.94M | $131.20M | $124.56M | $46.91M |
| Non-Equity Reserves | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Preferred Stock - Carrying Value | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Common Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Shareholders Equity | $510.61M | $307.83M | $231.34M | $319.11M | $256.39M | $-72.97M | $-27.59M | $-19.59M |
| Accumulated Minority Interest | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $510.61M | $307.83M | $231.34M | $319.11M | $256.39M | $-72.97M | $-27.59M | $-19.59M |
| Total Liabilities & Stockholders Equity | $560.38M | $339.89M | $261.85M | $353.49M | $288.33M | $58.23M | $96.97M | $27.32M |
| Book Value Per Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Tangible Book Value Per Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Full-Time Employees | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price to Book Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Invested Capital | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Quick Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Current Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|
| Net Income | $-160.87M | $-100.84M | $-107.49M | $-71.32M | $-56.69M | $-49.31M | $-9.55M | $-11.22M |
| Depreciation | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Funds (Non Cash) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Funds from Operations | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Extraordinary Item | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Changes in Working Capital | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Taxes Payable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash from Operating Activities | $-134.59M | $-75.79M | $-86.69M | $-69.13M | $-50.91M | $-36.71M | $-16.25M | $8.24M |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Assets From Acquisitions | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Sale of Fixed Assets and Businesses | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Purchase or Sale of Investments | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Purchase of Investments | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Sale Or Maturity of Investments | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Uses | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Sources | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash from Investing Activities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Change in Capital Stock | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Repurchase of Common Pref Stock | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Sale of Common Pref Stock | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Proceeds from Stock Options | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Issuance or Reduction of Debt, Net | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Change in Long Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Issuance of Long Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Reduction of Long Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Financing Active Other Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Financing Activities Uses | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash from Financing Activities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Exchange Rate Effect | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Change in Cash | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Preferred Dividends (Cash Flow) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price to Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Company coverage
Latest news
4DMT Announces Positive 2-Year Data from PRISM Phase 2b Clinical Trial in a Broad Wet AMD PopulationGlobeNewswire Inc. 4DMT Secures Strategic Credit Facility for up to $200 Million from Hercules CapitalGlobeNewswire Inc. Age-related Macular Degeneration Clinical Trial Pipeline: DelveInsight Highlights Major Advances, Transformative Therapies, and 90+ Leading Players Wheeling the Therapeutics LandscapeGlobeNewswire Inc. 4DMT to Participate in Upcoming Investor ConferencesGlobeNewswire Inc. 4DMT Appoints Kristian Humer as Chief Financial OfficerGlobeNewswire Inc. 4DMT Announces Exclusive License Agreement with Otsuka Pharmaceutical Co., Ltd. for Development and Commercialization of 4D-150 in Asia-PacificGlobeNewswire Inc. GenVivo Strengthens Oncology Leadership with Appointment of Noriyuki Kasahara, M.D., Ph.D., as Chief Scientific OfficerGlobeNewswire Inc. 4dMT Revenue Jumps 200 Percent in Q2The Motley Fool
Show 12 more stories
4DMT Reports Second Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming MilestonesGlobeNewswire Inc. 4DMT Announces Presentations at 43rd Annual Scientific Meeting of the American Society of Retina SpecialistsGlobeNewswire Inc. Gene Therapy in Ophthalmology Industry Report 2025-2035: Global Market Poised for Growth as Inherited Retinal Disease Cases Surge WorldwideGlobeNewswire Inc. 2025 Market Prospects of Adeno-Associated Virus Vectors in Gene Therapy Pipeline: 200 Pipeline Drugs and the Strategic Workings of 180+ CompaniesGlobeNewswire Inc. Cell and Gene Therapies in Rare Disorders Market to Skyrocket Across the 7MM During the Forecast Period (2025–2034) | DelveInsightGlobeNewswire Inc. 4DMT to Participate in Upcoming Investor ConferencesGlobeNewswire Inc. 4DMT Presents Positive 52-Week Results from Phase 2b Cohort of PRISM Wet AMD Study and Long-term Durability Data Supporting 4D-150 4FRONT Global Registration ProgramGlobeNewswire Inc. FDMT Investors Have Opportunity to Join 4D Molecular Therapeutics, Inc. Securities Fraud Investigation with the Schall Law FirmBenzinga 4DMT to Participate in the 2024 Cantor Global Healthcare ConferenceGlobeNewswire Inc. 4D Molecular Therapeutics tumbles following mid-stage clinical study results - Investing.comInvesting.com 4d Molecular Therapeutics CEO sells $290k in stock - Investing.comInvesting.com 4D Molecular Therapeutics officer sells $90,757 in stock By Investing.com - Investing.com AustraliaInvesting.com
Insider Trading
View AllInsider
Type
Shares
Price
Value
Date
Company
About the company
4D Molecular Therapeutics, Inc. is a clinical-stage gene therapy company that engineers therapeutic agents by leveraging its proprietary adeno-associated virus (AAV) vector technology. The company's developmental efforts are concentrated across a trio of therapeutic fields: ophthalmology (eye conditions), cardiology (heart ailments), and pulmonology (respiratory disorders). Within its active pipeline, three specific product candidates have advanced into clinical trial phases, all currently undergoing Phase 1/2 clinical assessment: 4D-125 is being evaluated for the treatment of X-linked retinitis pigmentosa. 4D-110 targets choroideremia. 4D-310 is focused on addressing Fabry disease. Beyond these, two Investigational New Drug (IND) candidates are in development: 4D-150, aimed at combating wet age-related macular degeneration, and 4D-710, designed to tackle cystic fibrosis lung disease. To advance its mission, 4D Molecular Therapeutics, Inc. actively engages in research and development partnerships with entities such as uniQure, CRF, Roche, and CFF. The firm commenced operations in 2013 and maintains its headquarters in Emeryville, California.
Discover more
You may be interested in